

- Bisphosphonates (Cont.):**
 for bone pain, 61, 119e-4
 for fibrous dysplasia, 426e-7
 for hypercalcemia, 314, 610, 2480t, 2481
 for metastatic bone disease, 119e-4
 for metastatic breast cancer, 530
 for multiple myeloma, 717
 for osteoporosis treatment, 2499–2501, 2500f, 2504
 for Paget's disease of bone, 426e-3–4, 426e-3t
 prophylactic
 in breast cancer, 529
 in osteoporosis, 2383
 in prostate cancer, 586
- Bite cells,** 655
- Bite-wounds, 167e-1**
 antibiotic prophylaxis, 167e-3
 approach to the patient, 945t
 cat. *See* Cat(s), bite-wounds
 dog. *See* Dog(s), bite-wounds
 epidemiology of, 167e-1
 human, 167e-2, 167e-3t, 830
 infections of, 167e-1–2, 167e-3t
 other animals, 167e-1–2
 rabies and tetanus prophylaxis, 167e-3
 treatment of, 167e-2–3, 167e-3t, 832t
- Bithionol,** 389t
- Bitot's spots,** 96e-6
- Bitter taste sensation,** 212
- Bivalirudin**
 action of, 754
 discontinuation before lumbar puncture, 443e-1
 vs. heparin, 754
 for heparin-induced thrombocytopenia, 728, 1461
 for myocardial infarction, 1597, 1598t
 in PCI, 296e-1
 pharmacology of, 753t
- BK-A (basophil kallikrein of anaphylaxis),** 372e-15t
- BK virus infection**
 in cancer patient, 490
 in transplant recipient
 after HSCT, 920t, 923
 after kidney transplant, 924t, 925, 926, 1831
- Black Creek Canal virus,** 1307t
- Black Death,** 261e-5
- Black hairy tongue,** 240t
- Blackhead,** 351
- Blackout,** 2724
- Black sea urchin envenomation,** 2740
- Black widow spider bite,** 105, 2747–2748
- Bladder**
 distention of, 286
 dysfunction of, 2660, 2663
 obstruction of, 104
 pain in, **60e-1**. *See also* Interstitial cystitis/
 bladder pain syndrome
- Bladder cancer, 575**
 adenocarcinoma, 575
 carcinoma of unknown primary and, 120e-2t
 chemotherapy-related, 575, 622–623
 clinical features of, 576
 deaths from, 467t, 575
 diagnosis of, 576
 epidemiology of, 575
 incidence of, 467t, 468f, 575
 pathogenesis of, 575–576
 pathology of, 575
 prognosis of, 577t
 risk factors for, 575
 staging of, 575, 576, 576f
 superficial, 577t
 transitional cell, 575
 treatment of, 576–577, 577t
- Bladder neck obstruction,** 1805
- Blastic NK cell lymphoma,** 135e-4
- Blastic phase, in CML,** 693–694
- Blast injury,** 457e-1, 457e-2
- Blastocystis hominis infection,** 1409
- Blastomyces spp.,** 145e-2t, 145e-3, 1338, 1338f
- Blastomyces spp. infections, 1337**
 approach to the patient, 1338
 clinical features of, 234, 829, 836, 908t, 1338
 diagnosis of, 1338
 epidemiology of, 1337
 in immunocompromised patient, 925t
 pathogenesis of, 1337–1338
 prognosis of, 1338
 treatment of, 1338–1339, 1338t
- Blau's syndrome,** 2215
- Bleeding, 400**
 approach to the patient, **403**
 in chronic kidney disease, 1818
 in DIC, 737
 drug-induced, 404, 404t
 fondaparinux, 753
 heparin, 751
 low-molecular-weight heparin, 753
 warfarin, 756
 gastrointestinal. *See* Gastrointestinal bleeding
 in hemophilia, 734
 history in, 403–404
 laboratory evaluation of, 405–407
 in liver disease, 739t
 systemic diseases that cause/exacerbate, 404
 variceal. *See* Variceal bleeding
- Bleeding time,** 405
- Bleomycin**
 action of, 103e-13
 adverse effects of, 103e-9t, 103e-13, 590
 cutaneous, 379, 2218t
 gonadal dysfunction, 103e-25
 hair loss, 380
 hemolytic-uremic syndrome, 1796
 in hyperbaric oxygen therapy, 477e-2
 hyperpigmentation, 360, 360t
 nausea and vomiting, 103e-25
 neurologic, 1794
 pulmonary, 489, 590, 621, 1797
 pulmonary fibrosis, 103e-13
 Raynaud's phenomenon, 590, 623, 1649
 for gestational trophoblastic disease, 597
 for ovarian germ cell tumors, 594
 for pericardial effusion, 474
 for pleural effusion, 474
 for testicular cancer, 590
- Blepharitis,** 199, 2746
- Blepharoptosis,** 207
- Blepharospasm,** 2620, 2648–2649
- Blinatumomab,** 103e-22
- Blind loop syndrome. See** Bacterial overgrowth
 syndromes
- Blindness. See** Visual loss
- Blind spot,** 197
- Blink reflexes,** 442e-6
- Blister beetle,** 2750
- Blister cells,** 655
- Blistering/vesicant agents,** 262e-1t, 262e-2t. *See also* Sulfur mustard
- BLM gene mutations,** 101e-6t
- Blomstrand's lethal chondrodysplasia,** 2476f
- Blood**
 donation, directed/designated, 138e-6
 laboratory evaluation of
 automated microbial detection, 150e-3
 culture for pathogens, 150e-3, 150e-4t
 for parasite detection, 245e-1–5, 245e-6t
 peripheral blood smear. *See* Peripheral
 blood smear
 reference values for, 2754–2756t
 transfusions. *See* Transfusion(s)
- Blood-brain barrier,** 33, 37f
- Blood culture,** 806, 819–820, 824
- Blood flukes. See** *Schistosoma* spp.
- Blood gases. See** Arterial blood gases
- Blood glucose monitoring,** 2409–2410. *See also*
 Glycemic control
- Blood group antigens and antibodies,** 138e-1,
 138e-1t
- Blood pressure. See also** Hypertension
 age-related changes in, 1611
 control of, 265e-3
 goals for, 1616, 1616t, 1626
 measurement of, 1444–1445, 1616, 1621–1622
- in pregnancy, 45
 regulation of, **1612**
 arterial pressure in, 1612f
 autonomic nervous system in, 1613
 intravascular volume in, 1612–1613
 renin-angiotensin-aldosterone system in,
 1613–1614, 1614f
 vascular mechanisms in, 1614–1615
 response to Valsalva maneuver, 2640, 2640t
 screening, 29t
- Blood products, contamination of**
 bacterial, 138e-6
 hepatitis viruses, 138e-3t, 138e-6, 735
 HIV, 138e-3t, 138e-6, 735, 1220t, 1222
 infectious, 138e-3t, 138e-6
 malaria, 1374
 screening for, 1222
T. cruzi, 1394
Yersinia, 1077
- Blood substitutes,** 662
- Blood urea nitrogen (BUN)**
 causes of abnormal values, 464t
 in hyponatremia, 301
 in hypovolemia, 298
 in nutritional assessment, 464t
 in prerenal azotemia, 298
- Blood vessels**
 biology of, **265e-1**
 engineered tissue for replacement of, 92e-3t
 origin of vascular cells, 265e-1
 pharmacogenetics of, 265e-4–5
 regeneration of, 265e-4
 smooth muscles of, 265e-1f, 265e-3–4
 in tumor angiogenesis, 102e-13–15, 102e-14f,
 102e-16f
 vascular cell biology of, 265e-1–4
- Blood volume,** 332e-10–11, 332e-10f
- Bloom's syndrome,** 101e-6t, 375e-1, 427
- “Blueberry muffin syndrome,”** 230e-1, 230e-2t.
See also Rubella (German measles),
 congenital
- “Blue bloaters,”** 1704
- Bluebottle jellyfish sting,** 2739
- Blue halo effect,** 328
- Blue light, for actinic keratosis,** 386
- Blue macules,** 360
- Blue nevus,** 364t, 367
- Blue River virus,** 1307t
- Blue rubber bleb syndrome,** 364t, 367
- “Blue toe” syndrome,** 1646, 1647f
- Blumer's shelf,** 534
- B lymphocytes. See** B cell(s)
- BMI. See** Body mass index (BMI)
- Bmi-1* gene,** 89e-2, 89e-4
- BNP. See** B-type natriuretic peptide (BNP)
- Bocaviruses,** 1197
- Boceprevir**
 action of, 215e-11
 adverse effects of, 2047
 for chronic HCV infection, 2044, 2045–2046t,
 2047–2048
 drug interactions of, 2047
- Body composition,** 71, 73t, 74f
- Body fat,** 6e-4, **462**. *See also* Obesity
- Body fluids**
 composition of, 295–297
 detection of parasites in, 245e-1–2, 245e-6t
 specimen collection and transport, 150e-4–5t
- Body image,** 7e-2
- Body lice (*Pediculus humanus*),** 1146, 2745–2746
- Body mass index (BMI)**
 calculation of, 415e-1, 415e-1f, 462, 2392
 nutritional status and, 98e-1t
 reference values for, 2393t
- Body plethysmography,** 306e-6
- Body temperature,** 123–124
- Boerhaave's syndrome,** 98, 1910
- Bohr effect,** 323, 393, 632, 632f, 636
- Bolivian (Machupo) hemorrhagic fever,** 1320
- Bombay phenotype,** 138e-1
- Bone**
 growth of, 2456
 metabolism of, 2454–2456, 2455f
 remodeling of, 2456, 2456f, 2467